Merck, Pfizer sign diabetes drug collaboration

04/30/2013 | Reuters · Genetic Engineering & Biotechnology News

Pfizer and Merck agreed to jointly develop and market the former's investigational type 2 diabetes drug ertugliflozin both as a standalone product and in combination with metformin and Merck's Januvia, or sitagliptin. The deal entitles Pfizer to as much as $60 million in upfront and milestone fees as well as additional payments if certain targets are reached. Merck and Pfizer said they would split potential revenue and some costs on a 60-40 basis.

View Full Article in:

Reuters · Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Wayzata, MN
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ
Meridian Health Plan
Detroit, MI
Assistant Vice President - Dental Director
Bridgewater, NJ